Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 4/20 | 0.47 |
| ▸ | TERT | O14746 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5433501 | 0.84 | F10 (0.46) | F10MAPK14KDM4ESMN1; SMN2 | |
| SCHEMBL4784430 | 0.80 | F10 (0.62) | CYP1A2TSHRNFKB1MAOBMEN1 | |
| SCHEMBL5431357 | 0.79 | F10 (0.47) | KMT2AF10MAPK14NPC1 | |
| SCHEMBL8781065 | 0.78 | CYP4Z1 (0.57) | CYP1A2TSHRNFKB1MAOBMEN1 | |
| Hydrochloric Acid SCHEMBL8781047 | 0.77 | CYP4Z1 (0.56) | CYP1A2TSHRNFKB1MAOBMEN1 | |
| SCHEMBL5437504 | 0.77 | RHOC (0.52) | MEN1KMT2AF10KDM4ESMN1; SMN2 | |
| SCHEMBL2639862 | 0.77 | MKNK1 (0.46) | F10MAPK14 | |
| SCHEMBL5433368 | 0.76 | F10 (0.40) | MEN1KMT2AF10MAPK14 | |
| SCHEMBL4748205 | 0.75 | NR4A1 (0.53) | TSHRMEN1KMT2AF10MAPK14 | |
| SCHEMBL5429383 | 0.75 | ROCK1 (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129361-A1 | LACTAM-CONTAINING DIAMINOALKYL, Beta-AMINOACIDS, Alpha-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-07 | — | — | US | claimed |
| US-20070129361-A1 | LACTAM-CONTAINING DIAMINOALKYL, Beta-AMINOACIDS, Alpha-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129361-A1 | LACTAM-CONTAINING DIAMINOALKYL, Beta-AMINOACIDS, Alpha-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | PEPD, XPNPEP1, METAP1 | CYP1A2 2248/4885TSHR 3524/4885NFKB1 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.